GSK and Daiichi Sankyo Launch Vaccine Venture in Japan - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

GSK and Daiichi Sankyo Launch Vaccine Venture in Japan


ePT--the Electronic Newsletter of Pharmaceutical Technology

GlaxoSmithKline (GSK) and Daiichi Sankyo have formed a joint venture that they claim will create the biggest vaccines company in Japan. The joint venture will seek to improve access to vaccinations in Japan, as well as introduce new vaccines and create better and more convenient combination vaccines.

The joint venture will hold the development and commercial rights for the companies’ existing preventative vaccines. It will also supply globally recommended vaccines in Japan including those for Human Papillomavirus, Rotavirus, seasonal flu, mumps, Diphtheria Pertussis, and Measles Rubella. Both companies will sell their respective vaccines into the joint venture at agreed-upon prices and receive sales synergies in return.

In Japan, many vaccines that contribute to disease prevention in other advanced countries are not used. In a statement, the companies explain that the joint venture will combine GSK’s pipeline and technology with Daiichi Sankyo’s knowledge and experience of the Japanese market and logistics to increase access to vaccines for all age groups.

The companies are investing a minimal cash investment of 100 million Yen (approximately $1.2 million) to cover the start-up capital requirements. Profits will be divided equally between the companies with a portion going toward funding ongoing capital needs of the joint venture. The new company will be called Japan Vaccine Co., Ltd., and will commence business on July 2, 2012. As new vaccines in the development pipeline are approved, the joint venture will be expanded.

According to Christophe Weber, president-designate of GSK Vaccine, the collaboration is part of the company’s strategy to increase its presence in key growth markets. In a press statement, he said, “We are very pleased to be partnering with Daiichi Sankyo... Both companies have strong track records in commercialization and, in combination, will create further significant economies of scale in the development and distribution of vaccines in the Japanese market.”

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here